

References

Abdul-Ghani MA, Tripathy D and DeFronzo RA(2006) Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. *Diabetes Care.*;29(5):1130-9.

Angeli A and Terzolo M.(2002) Adrenal incidentaloma – a modern disease with old complications. *J Clin Endocrinol Metab* ;87:4869-71.

Arafah BM, Prunty D, Ybarra J, Hlavin ML and Selman WR (2000) The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas. *J Clin Endocrinol Metab.*;85(5):1789-93.

Arlt W and Allolio B.(2003) Adrenal insufficiency. *Lancet*;361:1881-93.

Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F and Chrousos GP.(2003) Diagnosis and complications of Cushing's syndrome: A consensus statement. *J Clin Endocrinol Metab* ;88:5593-602.

Aron DC.(2001) The adrenal incidentaloma: disease of modern technology and public health problem. *Rev Endocr Metab Disord* ;2:335-42.

Aronoff SL, Berkowitz K, Shreiner B and Want L (2004) Glucose Metabolism and Regulation: Beyond Insulin and Glucagon. *Diabetes Spectrum.*;17(3):183-190

Asteria C, Giovanardi A, Pizzocaro A, Cozzaglio L, Morabito A, Somalvico F and Zoppo A (2008) US-elastography in the differential diagnosis of benign and malignant thyroid nodules. *Thyroid.* ;18(5):523-31.

Ayala AR, Danese MD, Ladenson PW (2000) When to treat mild hypothyroidism. *Endocrinol Metab Clin North Am* 29:399–415

Barzon L, Sonino N, Fallo F, Palu G and Boscaro M.(2003) Prevalence and natural history of adrenal incidentalomas. *Eur J Endocrinol* ;149:273-85.

Beckman JA, Creager MA and Libby P. (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. *JAMA.*; 287: 2570–2581

Bernet V. (2010) Approach to the patient with incidental papillary microcarcinoma. *J Clin Endocrinol Metab.*;95(8):3586-92.

Bernini GP, Moretti A, Oriandini C, Bardini M, Taurino C and Salvetti A. (2005) Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas. *Br J Cancer*;92:1104-9.

Bilezikian JP, Khan AA and Potts JT Jr (2009) (Third International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism). Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. *J Clin Endocrinol Metab.*;94:335-339

Bilzekian JP, Potts JT and Fuleihan GE-H. (2002) Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J. Clin. Endocrinol. Metab; 87(12): 5353-5361

Biondi B (2008) Should we treat all subjects with subclinical thyroid disease the same way? Eur. J. Endocrinol.;159(3):343-5.

Biondi B and Cooper DS(2008) The Clinical Significance of Subclinical Thyroid Dysfunction Endocr. Rev.; 29: 76 - 131.

Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S and Lombardi G.(2005)Subclinical hyperthyroidism: clinical features and treatment options. European Journal of Endocrinology.; 152:1–9

Blake DR, Meigs JB, Muller DC, Najjar SS, Andres R and Nathan DM. (2004) Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. Diabetes.;53(8):2095-100.

Boelaert K. (2009) The association between serum TSH concentration and thyroid cancer.Endocr. Relat. Cancer 16, 1065-1072.

Boelaert K and Franklyn JA. (2005) Thyroid hormone in health and disease. J. Endocrinol.;187(1):1-15.

Buurman H and Saeger W.(2006) Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. Eur. J. Endocrinol. 154, 753-758.

Canaris GJ, Manowitz NR, Mayor G and Ridgway EC.(2000) The Colorado Thyroid Disease Prevalence Study. Arch. Intern. Med.; 160:526-534

Caplan RH(2006) Subclinical hormone secretion by incidentally discovered adrenal mass. Arch Surg . 129 : 291-296

Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA and Giustina A. (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf).;65(2):265-73.

Chammas MC, Gerhard R, de Oliveira IR, Widman A, de Barros N and Durazzo M.(2005) Thyroid nodules: evaluation with power Doppler and duplex Doppler ultrasound. Otolaryngol Head Neck Surg.;132(6):874-82.

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A and Laakso M (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet.;359:2072–7.

Chiodini I.(2011) Clinical review: Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab. ;96(5):1223-36.

Chiodini I, Guglielmi G, Battista C, Carnevale V, Torlontano M and Cammisa M. (2004) Spinal volumetric bone mineral density and vertebral fractures in female patients with adrenal incidentalomas: the effects of subclinical hypercortisolism and gonadal status. J Clin Endocrinol Metab ;89:2237-41.

Christ-Crain M, Meier C, Huber PR, Staub J-J and Muller B (2004)

Effect of l-thyroxine replacement therapy on surrogate markers of skeletal and cardiac function in subclinical hypothyroidism.

Endocrinologist.;14(3):161-166.

Coco G, Dal Pra C, Presotto F, Albergoni MP, Canova C, Pedini

B, Zanchetta R, Chen S, Furmaniak J, Rees Smith B, Mantero F

and Betterle C. (2006) Estimated risk for developing autoimmune

Addison's disease in patients with adrenal cortex autoantibodies. J Clin

Endocrinol Metab.;91(5):1637-45.

Col NF , Surks MI and Daniels GH (2004) Subclinical thyroid disease:

clinical applications. JAMA, 291: 239-243

Connor, S. E. and Penney, C. C.(2003) MRI in the differential

diagnosis of a sellar mass. Clin. Radiol. 58, 20-31.

Cooper DS (2001) Subclinical hypothyroidism. N. Engl. J. Med.

;345(4):260-265.

Cooper DS (2007) Approach to the Patient with Subclinical

Hyperthyroidism. J. Clin. Endocrinol. Metab.; 92: 3 - 9.

Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ,

Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI,

Steward DL and Tuttle RM(2009) Revised American Thyroid

Association management guidelines for patients with thyroid nodules and

differentiated thyroid cancer. Thyroid. ;19(11):1167-214.

Daems T, Verhelst J, Michotte A, Abrams P, De Ridder D and Abs R.

(2009) Modification of hormonal secretion in clinically silent pituitary

adenomas. Pituitary.;12(1):80-6.

Daly AF, Burlacu MC, Livadariu E and Beckers A. (2007)The epidemiology and management of pituitary incidentalomas. Hormone Research ;68(suppl. 5): 195–198.

Davies L and Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA.;295(18):2164-7.

Dean DS and Gharib H.(2008) Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab. ;22(6):901-11.

De Bellis A A, Falorni A, Laureti S, Perrino S, Coronella C, Forini F, Bizzarro E, Bizzarro A, Abbate G and Bellastella A. (2001) Time course of 21-hydroxylase antibodies and long-term remission of subclinical autoimmune adrenalitis after corticosteroid therapy: case report. J Clin Endocrinol Metab. ;86(2):675-8.

Dekkers OM, Pereira AM and Romijn JA. (2008) Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. The Journal of Clinical Endocrinology and Metabolism; 93: 3717–3726.

Díez JJ and Iglesias P (2009) An analysis of the natural course of subclinical hyperthyroidism. Am. J. Med. Sci.;337(4):225-32.

Duggal J, Singh S, Barsano CP and Arora R.(2007) Cardiovascular risk with subclinical hyperthyroidism and hypothyroidism: pathophysiology and management. J. Cardiometab. Syndr.;2(3):198-206.

Duntas LH and Wartofsky L(2007). Cardiovascular risk and subclinical hypothyroidism: focus on lipids and new emerging risk factors: what is the evidence? Thyroid.;17(11):1075-1084.

Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML and McCutcheon IE.(2004) The prevalence of pituitary adenomas: a systematic review.Cancer.;101(3):613-9.

Fainstein Day P, Guitelman M, Artese R, Fiszledjer L, Chervin A, Vitale NM, Stalldecker G, De Miguel V, Cornaló D, Alfieri A and Mallea Gil MS.(2004) Retrospective multicentric study of pituitary incidentalomas. Pituitary.;7(3):145-8.

Falorni A(2009) Early subclinical Addison's disease. Endocrine Abstracts 20 S9.3

Fatourechi V (2009) Subclinical Hypothyroidism: An Update for Primary Care Physicians. Mayo Clinic Proceedings. vol. 84 no. 165-71

Fatourechi V, Lankarani M, Schryver PG, Vanness DJ, Long KH and Klee GG. (2003) Factors influencing clinical decisions to initiate thyroxine therapy for patients with mildly increased serum thyrotropin (5.1-10.0 mIU/L). Mayo Clin Proc.;78(5):554-560.

Gharib H and Papini E. (2007)Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol. Metab. Clin. North Am. 36, 707-735

Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedüs Land Vitti P (2010) American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract. ; 16 Suppl 1:1-43.

Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA and McDermott MT.(2005) Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. *J. Clin. Endocrinol. Metab.*;90(1):581-5; discussion 586-7.

Giustina A, Barkan A, Casanueva FF.(2000) Criteria for cure of acromegaly: a consensus statement. *J Clin Endocrinol Metab* ;85:526–529.

Grumbach MM, Biller BMK, Braunstein GD, Campbell KK, Carney JA and Godley PA.(2003) Management of the clinically inapparent adrenal mass (incidentaloma). *Ann Intern Med.*;138:424-9.

Gunn IR and Gaffney D.(2004) Clinical and laboratory features of calcium-sensing receptor disorders: a systematic review. *Ann Clin Biochem.*;41:441–458.

Hadjidakis D, Tsagarakis S, Roboti C, Sfakianakis M, Ionomidou V and Raptis SA. (2003) Does subclinical hypercortisolism adversely affect the bone mineral density of patients with adrenal incidentalomas? *Clin Endocrinol (Oxf)*;58:72-7.

Hagag P, Revet-Zak I and Hod N.(2003) Diagnosis of normocalcemic hyperparathyroidism by oral calcium loading test. *J Endocrinol Invest.*;26:327–332.

Hagström E, Lundgren E, Rastad J and Hellman P. (2006) Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. *Eur J Endocrinol.*;155(1):33-9

Holick MF (2007). Vitamin D deficiency. *N Eng J Med.*;357:266-81

Hollowell JG, Staehling NW, Flanders WD Hannon WH, Gunter EW, Spencer CA and Braverman LE. (2002) Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab.*;87(2):489-499.

Hughes K, Sandeep T and Adamson K. (2007) Subclinical Addison's disease. *Endocrine Abstracts* 13 P280

Hunt KJ, Williams K, Rivera D, O'Leary DH, Haffner SM and Stern MP (2003) Elevated carotid artery intima-media thickness levels in individuals who subsequently develop type 2 diabetes. *Arterioscler. Thromb. Vasc. Biol.*;23:1845–1850

Imaizumi M, Akahoshi M, Ichimaru S, Nakashima E, Hida A, Soda M, Usa T, Ashizawa K, Yokoyama N, Maeda R, Nagataki S and Eguchi K (2004) Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. *J. Clin. Endocrinol. Metab.*;89(7):3365-70.

Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR and Groop (2001) Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome. *Diabetes Care.*;24:683–689.

Kang HW, No JH, Chung JH, Min YK, Lee MS, Lee MK, Yang JH and Kim KW.(2004) Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas. *Thyroid.*;14(1):29-33.

Karavitaki N, Collison K, Halliday J, Byrne JV, Price P, Cudlip S and Wass JA.(2007) What is the natural history of nonoperated nonfunctioning pituitary adenomas? *Clin Endocrinol (Oxf).*;67(6):938-43.

Kernan WN, Viscoli CM, Inzucchi SE, Brass LM, Bravata DM, Shulman GI, and McVeety JC. (2005) Prevalence of abnormal glucose tolerance following a transient ischemic attack or ischemic stroke. Arch Intern Med.; 165: 227–233.

Khan AA, Bilezikian JP and Kung AW.(2004) Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab.;89:3319-3325.

Khan A, Grey A, and Shoback D.(2009) Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. ;94(2):373-81.

Kim M and Ladenson P (2011) Thyroid. In: Goldman L, Schaffer AI , eds. Cecil Medicine. 24th ed. Philadelphia, PA: Saunders Elsevier.ch. 233:pp 1450-1462

Kim TY, Kim WB, Ryu JS, Gong G, Hong SJ and Shong YK.(2005) 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope.;115(6):1074-8.

Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, and Walker EA (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med.;346:393–403.

Krikorian, A. and Aron, D. (2006) Evaluation and management of pituitary incidentalomas—revisiting an acquaintance.Nat. Clin. Pract. Endocrinol. Metab. 2, 138-145.

Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J and Salonen JT (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA*.;288:2709–16.

Levy MJ, Matharu MS, Meeran K, Powell M and Goadsby PJ.(2005) The clinical characteristics of headache in patients with pituitary tumours. *Brain*.;128:1921-30.

Libè R, Dall'Asta C, Barbetta L, Baccarelli A, Beck-Peccoz P and Ambrosi B. (2002) Long-term follow-up study of patients with adrenal incidentalomas. *Eur J Endocrinol*; 147:489-94.

Lowe H, McMahon DJ and Rubin MR (2007) Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. *J Clin Endocrinol Metab* ; 92(8):3001-5.

Lundgren E, Hagstrom EG, Lundin J, Winnerback MB, Roos J and Ljunghall S(2002) Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population based screening 8 yrs ago. *World J Surg*.;26:931-6.

Magalhães ME, Cavalcanti BA, Cavalcanti S and Giannella-Neto D. (2010) Could pre-diabetes be considered a clinical condition? opinions from an endocrinologist and a cardiologist. *Diabetol. Metab. Syndr.*;2:2.

Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ and Pio JR.(2004) Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. *Circulation*;110:1245-50.

Maruani G, Hertig A, Paillard M and Houillier P.(2003)

Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab.;88:4641-8.

Meigs JB, Larson MG, D'Agostino RB, Levy D, Clouse ME and Nathan DM (2002) Coronary artery calcification in type 2 diabetes and insulin resistance: the framingham offspring study. Diabetes Care.;25(8):1313-9.

Meyer C, Pimenta W, Woerle HJ, Van Haeften T, Szoke E, Mitrakou A, and Gerich J (2006) Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care.;29(8):1909-14.

Mitchell J and Parangi S. (2005) The thyroid incidentaloma: an increasingly frequent consequence of radiologic imaging. Semin Ultrasound CT MR. ;26(1):37-46.

Molitch ME. (2008) Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinology and Metabolism Clinics of North America; 37: 151–171.

Molitch, M. E.(2009) Pituitary tumours: pituitary incidentalomas. Best Pract. Res. Clin. Endocrinol. Metab. 23, 667-675.

Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, and Zinman B (2007) Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care.;30(3):753-9.

Nichols GA, Arondekar B and Herman WH. (2008) Complications of dysglycemia and medical costs associated with nondiabetic hyperglycemia. *Am.J.Manag.Care.*;14(12):791-8.

Nieman LK.(2010) Approach to the patient with an adrenal incidentaloma. *J Clin Endocrinol Metab.* ;95(9):4106-13.

Nieman LK. (2011) Adrenal cortex. In: Goldman L, SCHAFER AI , eds. *Cecil Medicine*. 24th ed. Philadelphia, PA: Saunders Elsevier.ch. 234:pp 1463-1469

Nussey SS and Whitehead SA(2001) *Endocrinology: An Integrated Approach*,Oxford: BIOS Scientific Publishers.

Osman F, Franklyn JA, Holder RL, Sheppard MC and Gammage MD.(2007) Cardiovascular Manifestations of Hyperthyroidism Before and After Antithyroid Therapy. *J. Am. Coll. Cardiol.*; 49:71-81

Paschke R and Ludgate M(1997) The thyrotropin receptor in thyroid diseases. *N Engl J Med* 337:1675–1681.

Palmieri EA, Fazio S, Lombardi G and Biondi B (2004) Subclinical hypothyroidism and cardiovascular risk: a reason to treat? *Treat Endocrinol.*; 3:233-244.

Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner S A, and Shoback DM.(2005) Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. *J Clin Endocrinol Metab.*;90:135-141.

Pietropaolo M and Le Roith D.(2001) Pathogenesis of diabetes: our current understanding. *Clin Cornerstone.*;4:1–16.

Potts JT Jr (2005) Diseases of parathyroid gland and other hyper – and hypocalcemic disorders. In: Kasper D, Fauci A, Longo D, Braunwald E, Hauser S, Jameson JL (eds) : Harrison principle of internal medicine 16th edition, McGraw-Hill. Ch.332:pp 2249-2268.

Ramlo-Halsted BA and Edelman SV.(1999) The natural history of type 2 diabetes. Implications for clinical practice. Prim Care.;26:771–89.

Rao SS, Disraeli P and McGregor T. (2004) Impaired glucose tolerance and impaired fasting glucose. Am. Fam. Physician.;69(8):1961-8.

Reiners C, Wegscheider K, Schicha H, Theissen P, Vaupel R, Wrbitzky R and Schumm-Draeger PM (2004) Prevalence of thyroid disorders in the working population of Germany: ultrasonography screening in 96,278 unselected employees. Thyroid. ;14(11):926-32.

Roberts LM, Pattison H and Roalfe A.(2006) Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive dysfunction? Ann. Intern. Med.;145(8):573-581

Rodondi N , Anne B. Newman, Eric Vittinghoff, Nathalie de Rekeneire, Suzanne Satterfield, Tamara B. Harris, and Douglas C. Bauer(2005) Subclinical Hypothyroidism and the Risk of Heart Failure, Other Cardiovascular Events, and Death , Arch. Intern. Med.; 165: 2460 - 2466.

Rosario PW.(2010) Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU/l: a prospective study. Clin. Endocrinol. (Oxf). 72(5):685-8.

Serhal D, Weil RJ and Hamrahian AH. (2008) Evaluation and management of pituitary incidentalomas. *Cleve Clin J Med*.;75(11):793-801.

Sgarbi JA , Villaca FG and Garbeline B (2003) The effects of early antithyroid therapy for subclinical hyperthyroidism. *J. Clin Endocrinol & Metab*, 88; 1672-1677

Sharma SK, Tandan SM, Saha PK, Gupta N, Kochupillai N and Misra NK. (2005) Reversal of subclinical adrenal insufficiency through antituberculosis treatment in TB patients: a longitudinal follow up. *Indian J Med Res.*;122(2):127-31.

Shen WT, Lee J, Kebebew E, Clark OH and Duh QY. (2006) Selective use of steroid replacement after adrenalectomy: lessons from 331 consecutive cases. *Arch Surg*;141:771-4.

Shrier DK and Burman KD. (2002) Subclinical hyperthyroidism: controversies in management. *Am Fam Physician.*;65(3):431-8.

Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M and Rubin MR.(2009) Presentation of asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. *J Clin Endocrinol Metab.*;94:351-365.

Silverberg SJ and Bilezikian JP. (2003)"Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease. *J Clin Endocrinol Metab.* ;88(11):5348-52.

Singer P (2005) Primary hypothyroidism due to other causes. In: Braverman LE, Utiger RD, eds. Werner, Ingbar's the thyroid: a fundamental and clinical text. 8th ed. Philadelphia: Lippincott, Williams & Wilkins; 745–754.

Singleton JR, Smith AG, Russell JW and Feldman EL. (2003) Microvascular complications of impaired glucose tolerance. Diabetes.;52(12):2867-73.

Sippel RS, Caron NR and Clark OH.(2007) An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up. World J Surg.;31(5):924-33.

Siren J, Tervahartiala P, Sivula A and Haapiainen R.(2000) Natural course of adrenal incidentalomas: seven-year follow-up study. World J Surg ;24:579-82.

Stern MP, Williams K and Haffner SM(2002) Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann. Intern. Med. 136:575–581

Sumner CJ, Sheth S, Griffin JW, Cornblath DR and Polydefkis M. (2003) The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. ;60(1):108-11.

Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF and Cobin RH (2004) Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management. JAMA; 291: 228 – 238

Tamsel S, Demirpolat G, Erdogan M, Nart D, Karadeniz M and Uluer H. (2007) Power Doppler US patterns of vascularity and spectral Doppler US parameters in predicting malignancy in thyroid nodules. Clin Radiol.;62(3):245-51.

Tauchmanová L, Rossi R, Biondi B, Pulcrano M, Nuzzo V and Palmieri EA.(2002) Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab; 87(11):4872-8.

Terzolo M, Bovio S, Pia A, Conton PA, Reimondo G and Dall'Asta C (2005) Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. Eur J Endocrinol.; 153:307-15.

Terzolo M, Bovio S, Reimondo G, Pia A, Osella G and Borretta G (2005) Subclinical Cushing's syndrome in adrenal incidentalomas. Endocrinol Metab Clin North Am;34:423-39.

Terzolo M, Reimondo G, Bovio S and Angeli A. (2004) Subclinical Cushing's syndrome. Pituitary.;7(4):217-23.

Tordjman KM, Greenman Y, Osher E, Shenkerman G and Stern N. (2004) Characterization of normocalcemic primary hyperparathyroidism. Am. J. Med.; 117(11):861-3.

Torgerson JS, Hauptman J, Boldrin MN and Sjostrom, L.(2004) Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27:151–161

- Tsagarakis S, Vassiliadi D and Thalassinou N.(2006)** Endogenous subclinical hypercortisolism: Diagnostic uncertainties and clinical implications. *J Endocrinol Invest*; 29:471-82.
- Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukkaanniemi S and Laakso M(2001)** Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med.*;344:1343–50.
- Turner HE, Moore NR, Byrne JV and Wass JA (1998)** Pituitary, adrenal and thyroid incidentalomas. *Endocr. Relat. Cancer*; 5, 131-150.
- Unwin N, Shaw J, Zimmet P and Alberti KG. (2002)** Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. *Diabet. Med.*;19:708–23.
- Valle LA and Kloos RT. (2011)** The prevalence of occult medullary thyroid carcinoma at autopsy. *J. Clin. Endocrinol. Metab.* 96, E109-E113.
- Wild S, Roglic G, Green A, Sicree R and King H.(2004)** Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* ;27(5):1047-53.
- Wilhelm SM, Robinson AV, Krishnamurthi SS and Reynolds HL(2007)** Evaluation and management of incidental thyroid nodules in patients with another primary malignancy. *Surgery* 142, 581-586.
- Wilson GR and Curry RW (2005)** Subclinical thyroid disease. *Am. Fam. Physician.*;72(8):1517-24.
- Yen PM. (2001)** Physiological and Molecular Basis of Thyroid Hormone Action .*Physiol. Rev*, 81: 1097 - 1142.

Young WF Jr.(2007) Clinical practice. The incidentally discovered adrenal mass. N Engl J Med;356:601-10.

Yuen KC, Cook DM, Sahasranam P, Patel P, Ghods DE, Shahinian HK and Friedman TC.(2008) Prevalence of GH and other anterior pituitary hormone deficiencies in adults with nonsecreting pituitary microadenomas and normal serum IGF-1 levels. Clin Endocrinol (Oxf).;69(2):292-8.

Zhu X, Gleiberman AS and Rosenfeld MG(2007) Molecular physiology of pituitary development: signaling and transcriptional networks. Physiol Rev.;87(3):933-63.